Loading...
PHVS logo

Pharvaris N.V.NasdaqGS:PHVS Stock Report

Market Cap US$2.0b
Share Price
US$29.95
US$46.94
36.2% undervalued intrinsic discount
1Y78.2%
7D-0.2%
Portfolio Value
​
View

Pharvaris N.V.

NasdaqGS:PHVS Stock Report

Market Cap: US$2.0b

Pharvaris (PHVS) Stock Overview

A late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. More details

PHVS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 91.3% below our estimate of its fair value

Risk Analysis

Makes less than USD$1m in revenue (€0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year


PHVS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Pharvaris N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pharvaris
Historical stock prices
Current Share PriceUS$29.95
52 Week HighUS$31.65
52 Week LowUS$14.59
Beta-2.34
1 Month Change12.47%
3 Month Change8.99%
1 Year Change78.17%
3 Year Change269.75%
5 Year Change44.69%
Change since IPO3.28%

Recent News & Updates

Recent updates

Seeking Alpha • Nov 23

Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating

Summary I initiate Pharvaris with a buy rating and $40 target price, driven by its differentiated oral bradykinin B2 antagonist franchise for HAE. PHVS's late-stage pipeline targets both on-demand and prophylactic HAE treatment, with pivotal phase 3 data expected by year-end 2025. Deucrictibant's validated mechanism, strong phase 2 results, and regulatory precedent de-risk the upcoming phase 3 readout, supporting a high probability of success of 90%+ (author's judgement). Key risks include clinical, commercial, and financing uncertainties, but the risk-reward profile remains attractive ahead of multiple catalysts. Read the full article on Seeking Alpha
Analysis Article • Jul 05

Here's Why We're Watching Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 17

We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 29

Pharvaris: Despite 30% Decline, Still Fair At Best

Summary Pharvaris is a pre-revenue biotech company with significant cash burn and a high development burden, making it a risky investment in a high-cost capital environment. Despite positive trial data, the company's valuation remains optimistic, considering the market size and potential outstanding development costs. The current market cap of $1 billion + $900 million development burden against a $2 billion gross value capture is not a great value setup. With only $300 million in liquidity and an estimated $900 million development burden, Pharvaris also has reflexivity risks. Read the full article on Seeking Alpha
Analysis Article • Dec 02

Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Aug 16

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jan 17

Pharvaris: Digging Deep For Sufficient Market Size

Summary Pharvaris is developing a molecule called Deucrictibant to treat acute hereditary angioedema (HAE) and provide prophylactic treatment. The market size for HAE is estimated to be around $2 billion, but that's digging deep and outside of the more profitable developed markets. Pharvaris has $440 million in available liquidity, including cash and a newly underwritten issue, but there is still a significant R&D burden and potential dilution in the company's future. At a $1.45 billion market cap, with outstanding burdens and a best-case market size at $2 billion according to our figures, we don't see the appeal here. Read the full article on Seeking Alpha
Analysis Article • Oct 09

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, Pharvaris ( NASDAQ:PHVS...
Analysis Article • May 13

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jan 11

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Sep 26

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 12

Pharvaris GAAP EPS of -€0.38

Pharvaris press release (NASDAQ:PHVS): Q2 GAAP EPS of -€0.38. Cash and cash equivalents were €201 million as of June 30, 2022, compared to €209 million as of December 31, 2021.
Seeking Alpha • Aug 22

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Pharvaris N.V. (NASDAQ:PHVS) dropped ~19% in the pre-market trading Monday after the Dutch biopharma announced that the FDA verbally notified its plans to issue a clinical hold on the clinical trials of hereditary angioedema candidate PHA121. The decision is based on a review of nonclinical data, and the agency intends to offer a formal clinical hold letter within the next 30 days. A small molecule bradykinin B2-receptor antagonist, PHA121, was undergoing clinical studies in the U.S. under two Investigational New Drug (IND) applications for HAE. “We are fully committed to working closely with the FDA to address the agency’s concerns,” PHVS Chief Executive Berndt Modig remarked.
Analysis Article • Jun 08

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 21

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Aug 25

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

PHVSUS PharmaceuticalsUS Market
7D-0.2%-1.5%2.6%
1Y78.2%30.4%26.2%

Return vs Industry: PHVS exceeded the US Pharmaceuticals industry which returned 33.5% over the past year.

Return vs Market: PHVS exceeded the US Market which returned 31.1% over the past year.

Price Volatility

Is PHVS's price volatile compared to industry and market?
PHVS volatility
PHVS Average Weekly Movement6.5%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: PHVS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: PHVS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015129Berndt Axel Modigpharvaris.com

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Pharvaris N.V. Fundamentals Summary

How do Pharvaris's earnings and revenue compare to its market cap?
PHVS fundamental statistics
Market capUS$1.97b
Earnings (TTM)-US$206.90m
Revenue (TTM)n/a
0.0x
P/S Ratio
-9.5x
P/E Ratio

Is PHVS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHVS income statement (TTM)
Revenue€0
Cost of Revenue€0
Gross Profit€0
Other Expenses€175.70m
Earnings-€175.70m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.69
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PHVS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/11 07:54
End of Day Share Price 2026/05/11 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharvaris N.V. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Steven SeedhouseCantor Fitzgerald & Co.
Jonathan WollebenCitizens JMP Securities, LLC